For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Ambit Biosciences Corporation

Calculating rank

USPTO Granted Patents = 39

% Expired Patents = 53.8

CIPO Patents = 2

EPO Patents = 16

Forward Citations = 110

Loading Chart...

Loading Chart...

49 inventors (with patents filed for the assignee):

Mark W Holladay (17 out of 25 patents)

Eduardo Setti (12 out of 19 patents)

Qi Chao (11 out of 26 patents)

4. Martin W Rowbottom (10 out of 41 patents)

5. Shripad S Bhagwat (9 out of 43 patents)

6. Sunny Abraham (8 out of 18 patents)

7. Gang Liu (8 out of 66 patents)

8. Kelly G Sprankle (7 out of 22 patents)

9. Michael J Hadd (7 out of 14 patents)

10. Andiliy Gokching Lai (7 out of 19 patents)

11. David J Lockhart (6 out of 61 patents)

12. Brian T Campbell (5 out of 17 patents)

13. Raffaella Faraoni (5 out of 5 patents)

14. Hitesh K Patel (5 out of 6 patents)

15. Pietro Ciceri (4 out of 6 patents)

Core Competencies:

Kinase Modulators

Heterocyclic Compounds

JAK Kinase

RAF Kinase

Proliferative Diseases

Biaryl Acetamide

Optically Active Compounds

Imidazolothiazole

Pharmaceutical Compositions

Combination Therapy

Pyrrole Compounds

DNA Display

39 patents: Sort by Forward Citations

1. 10053430 - RAF kinase modulator compounds and methods of use thereof (2018-08-21),

2. 9938261 - Heterocyclic compounds and methods of use thereof (2018-04-10),

3. 9730937 - RAF kinase modulator compounds and methods of use thereof (2017-08-15),

4. 9725465 - Biaryl acetamide compounds and methods of use thereof (2017-08-08),

5. 9675549 - Tablet containing composite with cyclodextrin (2017-06-13),

6. 9611253 - Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith (2017-04-04),

7. 9585892 - Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith (2017-03-07),

8. 9555040 - Methods of treating proliferative diseases (2017-01-31),

9. 9452167 - Heterocyclic compounds and methods of use thereof (2016-09-27),

10. 9320739 - RAF kinase modulator compounds and methods of use thereof (2016-04-26),

11. 9308207 - JAK kinase modulating compounds and methods of use thereof (2016-04-12),

12. 9296722 - Azolyl urea compounds and methods of use thereof (2016-03-29),

13. 9295672 - Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof (2016-03-29),

14. 9284332 - Process for the preparation of imidazo[2,1-B][1,3]benzothiazole derivatives (2016-03-15),

15. 8969587 - RAF kinase modulator compounds and methods of use thereof (2015-03-03),

Company Overview

Ambit Biosciences Corporation is a biotechnology company based in San Diego, California, specializing in the development of innovative therapies for cancer and other serious diseases. The company focuses on advancing targeted therapies and precision medicine, leveraging its expertise in drug discovery and development. Ambit is committed to addressing unmet medical needs through its research in molecular biology and pharmacology, aiming to improve patient outcomes and enhance treatment options in oncology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

39 Patents

#156 in San Diego, CA

#2,094 in California

#8,830 in US

#17,465 in the World

San Diego, CA, United States of America

Ambit Biosciences Corporation

Forward Citations = 110

49 inventors:

Mark W Holladay (17 out of 25 patents)

Eduardo Setti (12 out of 19 patents)

Qi Chao (11 out of 26 patents)

4. Martin W Rowbottom (10 out of 41 patents)

5. Shripad S Bhagwat (9 out of 43 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ambit Biosciences Corporation. Retrieved from https://idiyas.com/company/ambit-biosciences

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…